Abstract:

Background: Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) continues to be a major global public health issue, in 2015, an estimated 36.7 million people were living with HIV/AIDS, since the start of the epidemic, an estimated 78 million people have become infected with HIV and 39 million people have died of HIV/AIDS related illness, around 40% all people living with HIV/AIDS do not know that they have the virus, the coverage of antiretroviral therapy (ART) is around 60%. Health facilities (HFs) need and extensive range of antiretroviral (ARV) drugs and related Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) commodities increase the risk of treatment interruption, antiretroviral resistance, treatment failure, morbidity and mortality. This is a study to assess magnitude and duration of stockout of HIV commodities in public health facilities.

Methodology: A cross-sectional conducted on September 2020 which employed both quantitative approach and phenomenology approach for qualitative study. Simple random procedure was used to obtain at least 96 sample size from the clusters to obtain targeted population, where each health facility was randomly selected.

Results: Majority of the health facilities were the dispensary level 68.2%, 9.1% were health center and 4.5% were regional, district and referral level. 72.7% of all health facilities faced the challenge of shockouts while 18.3% had no issues in the stockouts and the most drug that was out of stock was first line regime of ART tenofovir-lamivudin-doltegravir (TLD). The HIV diagnostic test and the co-trimoxazole prophylaxis tables were present during the time of survey. 86.4% of the facilities participated used dried blood sample (DBS), where they send to the referral hospital for analysis of testing exposed infants.